Biopharmaceuticals

Washington – – September 15, 2026 -- Clearsight Advisors served as exclusive sell-side advisor to Ambit RD, Inc. on its acquisition by Danforth Health, Inc., a portfolio company of Avesi Partners, in a deal announced by the firms.

Ambit brings patient-identification technology to Danforth's life sciences platform

Ambit RD specializes in commercial strategy, advanced analytics, and patient identification solutions for rare and specialty biopharma markets, operating through three service lines: Strategic Services, Analytics & Data Services, and Patient ID Services. The company helps biopharmaceutical organizations locate patients, speed therapy adoption, and engage healthcare providers across the clinical and commercial continuum.

Paramus, N.J. – – September 15, 2026 -- A prespecified secondary analysis of the landmark FIBRES trial found that Octapharma's fibryga (fibrinogen [human]) cut 24-hour allogeneic blood-product transfusion requirements by 19% versus cryoprecipitate in two overlapping patient subgroups, according to findings published in the Journal of Cardiothoracic and Vascular Anesthesia.

Non-critical and elective surgery patients showed the sharpest transfusion reductions

Among 634 patients classified as non-critical before surgery -- 86% of the primary trial population -- those receiving fibryga required 13.6 blood-product units on average versus 16.2 units for cryoprecipitate recipients, a 19% relative reduction. In the 466-patient elective-surgery subgroup, representing 63% of the primary population, fibryga patients received 11.7 units compared with 14.4 units for cryoprecipitate, matching the 19% relative reduction.

Los Angeles – September 15, 2026 -- Partillion Bioscience has secured a two-year, $2.1 million NIH Small Business Innovation Research (SBIR) award to scale its Cell-Cell-seq technology toward datasets of up to one million cell pairs. The grant, awarded by the National Institute of General Medical Sciences (NIGMS) under Award Number R44GM165220, is Partillion's 10th SBIR grant and brings the company's total non-dilutive federal funding past $8 million, roughly matching its private investment to date without additional equity dilution.

Barcelona, Spain – September 15, 2026 -- Altesa BioSciences reported that its investigational oral antiviral vapendavir significantly reduced two key inflammatory biomarkers, IP-10/CXCL10 and GM-CSF, in COPD patients experimentally infected with rhinovirus, according to data presented at the European Respiratory Society (ERS) International Congress 2026.

Vapendavir lowers airway inflammation markers in Phase 2a challenge study

Nasal lavage samples from COPD patients treated with vapendavir showed significantly lower levels of IP-10/CXCL10 and GM-CSF compared to placebo over the course of rhinovirus infection. Two additional biomarkers, IFN-α2a and IFN-λ1/IL-29, trended lower with treatment but did not reach statistical significance.

Jupiter, Florida – September 15, 2026 -- Cytonics Corporation has closed a financing campaign generating $4.8 million in gross proceeds, pushing its total capital raised to $47 million and expanding its investor base to approximately 8,000 shareholders.

Cytonics attracts 900 new investors as 35% of existing shareholders reinvest

The clinical-stage biotechnology company completed approximately 1,500 individual investments in the round, including roughly 900 first-time backers. Of the pre-raise shareholder base, 35% chose to invest again, according to the company. The raise brings cumulative funds secured through Regulation A and Regulation Crowdfunding offerings to $27 million.

New York City – September 15, 2026 -- Mice fed 30 percent fewer calories than their normal intake showed reduced levels of DNA mutations across multiple tissues, according to a study published September 9 in Cell by researchers at NYU Langone Health and University Hospitals Cleveland.

Researchers Measure Genome-Wide Mutation Reduction for the First Time

The study is the first to quantify how caloric restriction affects mutation patterns across a large portion of the genome, rather than in single genes as prior research had done. Using advanced DNA sequencing technology, the team tracked both substitution mutations, where one DNA letter replaces another, and insertion-deletion mutations, where DNA letters are added or removed.

The research was conducted in collaboration with the University of Texas Southwestern Medical Center and the National Institutes of Health.

Monroe, Ohio – September 15, 2026 -- CSafe, a provider of temperature-controlled shipping solutions for the life sciences industry, has appointed Will Romanowicz as Chief Legal Officer, effective September 9, 2026.

Romanowicz Brings Decade-Plus of Regulated-Industry Legal Experience

Romanowicz joins with more than ten years of legal, governance, and commercial leadership across FDA-regulated sectors, including biotech, agribusiness, SaaS, food & beverage, and supplements. He has worked with both large global public companies and late-stage startups.

Most recently, he held a combined legal and commercial role leading a cross-functional team responsible for legal affairs, government affairs, and external communications. Earlier in his career, he practiced corporate law, advising companies on governance, restructuring, and complex transactions.

South San Francisco, Calif. – September 15, 2026 -- Apeximmune Therapeutics said a peer-reviewed study published in Nature independently validates PLA2G2D as a novel immune checkpoint capable of overcoming resistance to anti-PD-1 cancer therapies, with the company's lead antibody AI-306 targeting an IND filing in the second quarter of 2027.

Two independent research teams identified the same target through different methods

Apeximmune's computational screen of more than 9,000 primary tumor samples from The Cancer Genome Atlas ranked PLA2G2D as its top novel checkpoint candidate, ahead of PD-1 and CTLA-4 in the same analysis. Working separately and without knowledge of Apeximmune's program, researchers at Erasmus University Medical Center in Rotterdam used spatial proteogenomic analysis of melanoma patient samples with divergent outcomes and arrived at PLA2G2D as a top hit in dendritic cell and macrophage populations linked to poorer prognosis.

The Woodlands, Texas – September 15, 2026 -- Cellipont Bioservices and Xiogenix have published a joint white paper showing that Xiogenix's ARES X20+ automated fill-finish platform maintained formulation volume accuracy of 98.2% at small scale and 103.6% at large scale across an approximately 17-fold increase in process scale.

The paper, titled "Scaling Cell and Gene Therapy Manufacturing with Automated Formulation and Fill-Finish," details Cellipont's evaluation of the platform across small and large-scale cell therapy manufacturing workflows.

Houston – September 15, 2026 -- ImmunoGenesis has appointed Reza Mazhari, Ph.D., and Mike Davis to its Board of Directors as the clinical-stage biotech advances its lead immunotherapy candidate toward key data readouts in mid-2027.

ImmunoGenesis has initiated a Phase 1b trial for lead asset IMGS-001

IMGS-001, a cytotoxic checkpoint inhibitor targeting PD-L1 and PD-L2, is being studied for immune-excluded tumors, a category that accounts for more than half of all cancers. James Barlow, President and CEO of ImmunoGenesis, said the new board members will help shape pipeline, partnering and fundraising strategy for the company's next growth phase.